• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Macular Degeneration  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Wei-Cheng Huang, MD; Jane-Ming Lin, MD; Chun-Chi Chiang, MD; Yi-Yu Tsai, MD, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the study by Bashshur and colleagues,¹ 0.1 mL of bevacizumab was injected intravitreally; paracentesis was performed only if intraocular pressure (IOP) was greater than 25 mm Hg or the optic nerve head was not adequately perfused 20 minutes after injection. They did not mention how many patients needed paracentesis. I would like to add some comments on the subject.

There are 3 articles^2-4 that discuss IOP changes following intravitreal bevacizumab and the necessity of paracentesis; however, the lack of consistency among their conclusions is controversial. Hollands et al³ suggest that clinicians should check IOP after injection or perform a preinjection paracentesis. In a study by Bakri et al,² no patients required paracentesis, but a few patients required IOP-lowering drops. Falkenstein et al⁴ reported that paracentesis is unnecessary. These studies, however, used only 0.05 mL of bevacizumab; . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab—Reply
Ziad F. Bashshur
Arch Ophthalmol. 2008;126(9):1315.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Ziad F. Bashshur, Alexandre Schakal, Rola N. Hamam, Christelle P. El Haibi, Rola F. Jaafar, and Baha’ N. Noureddin
Arch Ophthalmol. 2007;125(10):1357-1361.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Prophylactic Intraocular Pressure-Lowering Medication on Intraocular Pressure Spikes After Intravitreal Injections
Frenkel et al.
Arch Ophthalmol 2010;128:1523-1527.
ABSTRACT | FULL TEXT